Compare WING & APGE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | WING | APGE |
|---|---|---|
| Founded | 1994 | 2022 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Restaurants | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.4B | 4.7B |
| IPO Year | 2015 | 2023 |
| Metric | WING | APGE |
|---|---|---|
| Price | $173.57 | $132.87 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 27 | 13 |
| Target Price | ★ $295.92 | $109.67 |
| AVG Volume (30 Days) | 1.0M | ★ 5.1M |
| Earning Date | 04-29-2026 | 05-12-2026 |
| Dividend Yield | ★ 0.70% | N/A |
| EPS Growth | ★ 67.84 | N/A |
| EPS | ★ 1.08 | N/A |
| Revenue | ★ $696,853,000.00 | N/A |
| Revenue This Year | $17.20 | N/A |
| Revenue Next Year | $15.86 | N/A |
| P/E Ratio | $164.86 | ★ N/A |
| Revenue Growth | ★ 11.35 | N/A |
| 52 Week Low | $116.35 | $34.34 |
| 52 Week High | $381.45 | $133.85 |
| Indicator | WING | APGE |
|---|---|---|
| Relative Strength Index (RSI) | 62.95 | 81.38 |
| Support Level | $139.01 | $73.70 |
| Resistance Level | $204.64 | $133.16 |
| Average True Range (ATR) | 8.85 | 1.68 |
| MACD | 2.23 | 2.74 |
| Stochastic Oscillator | 89.53 | 98.03 |
Wingstop is a fast casual restaurant concept built around a simple chicken-centric menu. The firm primarily offers bone-in and boneless wings, tenders, and a chicken sandwich, customizable across 12 flavors. The banner generated $5.3 billion in system sales in 2025 across 3,056 units, with 85% located in the US. Wingstop largely operates as a franchisor, with 98% of units franchised, and earns revenue largely from collecting royalties and advertising fees paid by franchisees, with a smaller contribution from company-owned restaurant sales.
Apogee Therapeutics Inc is a clinical-stage biotechnology company engaged in advancing optimized, novel biologics with the potential for differentiated efficacy and dosing in the inflammatory and immunology (I&I) markets, including for the treatment of atopic dermatitis (AD), asthma, eosinophilic esophagitis (EoE), chronic obstructive pulmonary disease (COPD), and other I&I indications. . Its antibody programs are designed to overcome the limitations of existing therapies by targeting well-established mechanisms of action and incorporating antibody engineering to optimize half-life and other properties.